金融界8月25日消息，有投资者在互动平台向博思软件提问："公司员工持股计划为什么转成信托管理？ 难道公司不比信托公司了解公司自己？并且通过信托融资，融到资金只能投资国zhai等低收益产品，很 显然融资是亏本赚吆喝！这个事情存在诸多疑点，网上有人说这是利益输送，公司作何解释？" 针对上述提问，博思软件回应称："投资者您好，公司根据《上市公司实施员工持股计划试点的指导意 见》等有关法律、法规、规范性文件的规定，结合公司第三期员工持股计划的实际情况和员工意愿，公 司将此持股计划管理模式由自行管理变更为委托具备资产管理资质的专业机构进行管理，不涉及利益输 送及其他不正当的交易行为，详情敬请查阅公司于2024年9月24日发布的《关于变更第三期员工持股计 划相关事项的公告》，感谢您的关注。"责任编辑：栎树 ...

本文源自：金融界AI电报 8月25日早间，东风集团股份在港交所公告，于今天上午九时正起恢复买卖。因此，与该公司有关的所 有结构性产品亦将同时恢复买卖。该公司此前公告，子公司岚图汽车将以介绍上市方式登陆港股，东风 集团股份将同步完成私有化退市。根据公告，本次交易采用岚图汽车股权+现金对价支付，总体收购价 格为10.85港元/股，其中现金对价6.68港元/股，岚图股权对价4.17港元/股。 ...

专利摘要显示，本实用新型提供一种车间余热回收利用装置，属于能源回收技术领域，该车间余热回收 利用装置包括通风管道；T型槽，T型槽开设于通风管道的下内壁；T型滑块，T型滑块滑动连接于T型 槽内；吸热风扇，吸热风扇固定连接于T型滑块的上端；本装置通过螺杆螺纹连接于吸热风扇内可以使 吸热风扇更加方便拆卸除尘，减少了风扇因为灰尘堆积造成吸热风扇工作效率低的问题，并且更加节 能。 天眼查资料显示，玖龙纸业（沈阳）有限公司，成立于2010年，位于沈阳市，是一家以从事造纸和纸制 品业为主的企业。企业注册资本51805.7万美元。通过天眼查大数据分析，玖龙纸业（沈阳）有限公司 参与招投标项目57次，专利信息95条，此外企业还拥有行政许可251个。 作者：情报员 金融界2025年8月25日消息，国家知识产权局信息显示，玖龙纸业（沈阳）有限公司取得一项名为"一种 车间余热回收利用装置"的专利，授权公告号CN223258331U，申请日期为2024年10月。 本文源自：金融界 ...

Core Insights - The company reported a revenue of 3.585 billion yuan for the first half of 2025, representing a year-on-year growth of 15.1%, with a net profit attributable to shareholders of 604 million yuan, up 32.2% year-on-year [1] - The innovative drug business was a significant growth driver, generating 2.776 billion yuan in revenue, a 26.0% increase, accounting for 77.4% of total revenue [1] Revenue Breakdown - The neuroscience segment generated 1.249 billion yuan, accounting for 34.8% of total revenue, with a year-on-year growth of 37.3% [2] - The oncology segment reported revenue of 874 million yuan, making up 24.4% of total revenue, with a growth of 41.1% [2] - The autoimmune segment achieved revenue of 878 million yuan, representing 24.5% of total revenue, with a modest growth of 3.3% [2] Product Highlights - The strong growth in the neuroscience field is attributed to the continued expansion of the product Xianbixin® in the stroke injection market, which has captured approximately 29% market share [2] - The oncology segment features several key products, including Endu® and Envida®, which are recommended in multiple clinical practice guidelines [3] - The autoimmune segment's leading product, Aidesin®, has benefited over 1 million patients since its launch in 2012 [3] R&D Investment - The company increased its R&D investment to 1.028 billion yuan, a 68.0% increase year-on-year, representing 28.7% of total revenue [4] - Over the past decade, cumulative R&D investment has exceeded 10 billion yuan, supporting ongoing innovation [4] - The company has ten approved innovative drugs and over 60 projects in its pipeline [4] Strategic Collaborations - The company has established strategic partnerships with various international firms, enhancing its R&D pipeline and international presence [6] - Notable collaborations include licensing agreements with AbbVie and NextCure for innovative drug candidates [6] Marketing and Financial Health - The company has a comprehensive marketing network with approximately 4,179 personnel across China, covering over 3,000 tertiary hospitals and 17,000 other medical institutions [7] - As of June 30, 2025, the company reported cash and cash equivalents of 2.671 billion yuan, with a net operating cash flow of 867 million yuan [7] Industry Environment - The Chinese pharmaceutical industry is experiencing favorable policy changes that support innovative drug development, including expedited review processes [8] - The company aims to expand its market share and improve drug accessibility through its strong R&D capabilities and commercial strategies [8]

Group 1 - The core viewpoint of the articles highlights the significant growth potential of the AI industry in China, driven by government policies and technological advancements, with predictions indicating that the AI industry scale will exceed 10 trillion yuan by 2029 [1] - The 2025 World Artificial Intelligence Conference in Shanghai showcased breakthrough AI products from major companies like Tencent, Alibaba, and Baidu, marking a pivotal moment for the AI sector [1] - The Chinese government has emphasized the importance of large-scale commercialization of AI applications, leveraging the country's industrial system and market scale to foster innovation [1] Group 2 - The Hang Seng Hong Kong Stock Connect Technology Theme Index (HSSCITI.HI) was launched in 2023 to track the performance of leading technology companies listed in Hong Kong, focusing on a comprehensive AI industry chain [2] - This index stands out due to its systematic coverage of the entire AI value chain, including hardware, models, and application scenarios, which allows it to capture investment opportunities arising from AI technological breakthroughs [2][3] - The index's recent adjustment raised the individual stock weight limit from 10% to 15%, enhancing its concentration on leading technology firms and improving its ability to capture core industry returns [5] Group 3 - The high concentration strategy of the index aligns with the "winner-takes-all" logic in the AI industry, where leading companies dominate market share and innovation, resulting in superior performance [6] - The performance of the U.S. tech giants, often referred to as the "seven giants," illustrates the benefits of high concentration, with significant returns compared to broader indices [6] - The Hang Seng Hong Kong Stock Connect Technology Index is expected to show stronger performance and valuation recovery due to the acceleration of AI commercialization and continued inflow of capital [7][9]

本文源自：金融界AI电报 高盛进一步上调中国芯片制造商寒武纪的目标价50%至1,835元人民币，称主要原因为中国云计算资本 支出提高、芯片平台多样化、寒武纪研发投入增大。高盛分析师Verena Jeng等人在报告中将公司2025 年-2027年净利润预测分别上调59%、28%和29%，以反映更高的AI芯片出货量。报告称，8月中旬，中 国信息通信研究院宣布包括寒武纪在内的8家公司通过了DeepSeek适配测试，再次印证了该行对寒武纪 强大研发能力的积极看法。中国云计算资本开支增长，2024年晚些时候基础模型推出后，推理需求不断 增加。其客户将芯片平台多样化，以在关税不确定性和数据安全担忧下降低单一供应的风险。 ...

上述资讯只供参考，并非投资指引。 本文源自：财华网 【财华社讯】东风集团股份(00489.HK)公布，于今天（25/8/2025）上午九时正起恢复买卖。因此，与该 公司有关的所有结构性产品亦将同时恢复买卖。 出处：财华港股智能写手 ...

出处：财华港股智能写手 上述资讯只供参考，并非投资指引。 【财华社讯】毅高国际控股(08218.HK)公布，于今天（25/8/2025）上午九时正起恢复买卖。 本文源自：财华网 ...

Core Viewpoint - Xiangtan Electric responded to an investor inquiry regarding the manganese sources needed for lithium-rich manganese-based materials, indicating that both manganese oxide and manganese sulfate can be used as manganese sources [1] Group 1 - The company confirmed that lithium-rich manganese-based materials can utilize manganese oxide (Mn3O4) and manganese sulfate (MnSO4) as manganese sources [1]

Core Viewpoint - XianDao Intelligent Equipment Co., Ltd. is a leading global high-end intelligent equipment platform company, providing competitive intelligent manufacturing equipment and solutions for emerging and high-end manufacturing industries [1] Group 1: Company Overview - XianDao Intelligent submitted its Hong Kong IPO prospectus on February 25, which became invalid on August 25 after six months [1] - The company is recognized as the largest provider of intelligent equipment and solutions for the new energy sector, holding a 9.1% share of the global market, an increase of 3.3 percentage points from 2023 [1] Group 2: Market Position - According to the 2024 order value, XianDao holds a 22.4% share of the global lithium battery intelligent equipment market and a 23.8% share of the lithium battery intelligent logistics equipment market [1] - In terms of order value for 2024, XianDao is the largest provider of lithium battery intelligent equipment globally, with a 22.4% share of the global market and a 34.1% share of the Chinese market, both of which have shown consistent growth during the historical record period [1]